Obesity
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Obesity Home
    • Products
      Obesity Treatments
    • Professional Resources
      Product Resources Library
  • Sample Requests
    • Disease Education
      Obesity: A Chronic Disease
    • Treatment Guidelines
      AACE Obesity Guidelines
    • Additional Resources
      Organizations & Conferences Utilizing Your EHR
    • Product Education
      Product Education Library
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards
    • Support Programs
      Weight-Loss Support
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Medical Information
    Non-US Health Care Professionals
Wegovy™ (semaglutide) injection 2.4 mg logo
Important Safety Information | Patient Site
Prescribing Information
    • The Impact of Obesity
    • How Weight Loss Can Help
    • Causes of Obesity
    • How Wegovy™ Works
    • STEP 1 Results
    • STEP 4 Results
    • Cardiometabolic End Points
    • Common Adverse Events
    • Semaglutide Cardiovascular Safety Data
    • The Wegovy™ Pen
    • Prescribing Wegovy™
    • Dose-Escalation Schedule
    • Navigating Coverage Eligibility
    • Co-pay Cards
    • For Pharmacists
    • WeGoTogether™
    • Frequently Asked Questions
    • Product Supply Information
Wegovy™ (semaglutide) injection 2.4 mg logo

As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with a BMI of ≥30 kg/m2 (obesity), or ≥27 kg/m2 (overweight) in the presence of a weight-related comorbidity. Click for Limitations of Use.

Prescribing Information
Important Safety Information | Patient Site

We appreciate your interest in Wegovy®. We are currently experiencing Wegovy® supply shortages. To help answer patient questions, click here. To read an HCP letter from our president, click here.

Cost & Coverage

Navigating Coverage Eligibility

3 steps to find information on coverage and savings

1 Icon

On WegovyCoverage.com, you will be able to find out your patient’s coverage and estimated out-of-pocket costs in minutes

You will be able to:

  • Check your patient’s coverage status in minutes*
  • Estimate your patient’s co-pay amount even if a prior authorization (PA) is required†
  • Find restriction requirements and deductible information
  • Check your patient’s eligibility for savings

*If online benefit verification does not provide information on coverage, you can submit a Service Request Form. The NovoCare® team will conduct a benefit investigation and follow up with coverage and cost details.

†If there is no co-pay amount listed and a PA is requested, this means your patient has coverage, but the co-pay amount is unknown.

Wegovy coverage
2 icon

Once you have verified your patient’s benefits, then you can initiate the prior authorization process

Novo Nordisk collaborates with CoverMyMeds to offer you a convenient way to navigate the prior authorization (PA) process.

You can initiate a PA by visiting WegovyCoverage.com or accessing an existing no-cost covermymeds.com account or creating a new one:

Computer icon

Visit covermymeds.com

Phone icon

Call 1-866-452-5017

Benefits include:

  • Process requests for any medication and all plans
  • Submit PA renewals from previously submitted requests
  • Receive faster PA determinations, often in real time
  • Offer appeal assistance, if needed
3 icon

Once the PA is approved, your patients are ready to fill out their Wegovy™ prescription

Ask your patients to download the savings offer on SaveOnWegovy.com

Pay as little as $25
Pay as little as $25

Patients paying $25 who may need to temporarily step back their dose could pay as little as $0 for an additional 28-day supply by calling 1-833-4-Wegovy and pressing 2†

Wegovy™ patient saving card

*Eligibility and restrictions apply. Subject to a maximum savings of $200 per 28-day supply. If patients pay cash for their prescriptions, they can save up to $200 per 28-day supply (1 box) of Wegovy™. Novo Nordisk reserves the right to modify or cancel this program at any time. See terms and conditions at WegovyTerms.com.

†Eligibility and restrictions apply. For eligible commercially insured patients currently using a Wegovy™ savings offer, if such patients are prescribed a dose de-escalation within 21 days after the date of fill for the original dose. Subject to a maximum savings of $225 for up to a 28-day supply of Wegovy™. See terms and conditions at WegovyStepBack.com. Novo Nordisk reserves the right to modify or cancel this program at any time.

Wegovy™ patient saving card

Learn more about benefit verification at novocare.com.

Your eligible patients could save on Wegovy™

Get co-pay cards

Important Safety Information for Wegovy™ (semaglutide) injection 2.4 mg

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy™ causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy™ and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy™

Indication and Usage

Wegovy™ (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Limitations of Use

  • Wegovy™ contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist
  • The safety and effectiveness of Wegovy™ in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established
  • Wegovy™ has not been studied in patients with a history of pancreatitis


Important Safety Information cont.

Contraindications

  • Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy™. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not restart
  • Acute Gallbladder Disease: In clinical trials, cholelithiasis was reported by 1.6% of Wegovy™ patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Wegovy™-treated patients than in placebo-treated patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Hypoglycemia: Wegovy™ lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy™ patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy™ with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes
  • Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion
  • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist
  • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™
  • Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation

Adverse Reactions

  • The most common adverse reactions reported in ≥5% of patients treated with Wegovy™ are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease

Drug Interactions

  • The addition of Wegovy™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Wegovy™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy™

Use in Specific Populations

  • Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue Wegovy™. Discontinue Wegovy™ in patients at least 2 months before a planned pregnancy

Please click here for Wegovy™ Prescribing Information, including Boxed Warning.

Obesity
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Obesity Home
  • Product Information
    Products
    • Obesity Treatments
    Professional Resources
    • Product Resources Library
  • Sample Requests
  • Professional Education
    Disease Education
    • Obesity: A Chronic Disease
    Treatment Guidelines
    • AACE Obesity Guidelines
    Additional Resources
    • Organizations & Conferences
      Utilizing Your EHR
  • Patient Support
    Product Education
    • Product Education Library
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
    Support Programs
    • Weight-Loss Support

Wegovy™ is a trademark of Novo Nordisk A/S.

novoMEDLINK™ is a registered trademark of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

This website is intended for US Health Care Professionals.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2021 Novo Nordisk All rights reserved. US21SEMO00577 December 2021

Quick links

Request medication samples

Obesity treatment guidelines

Patient savings card offer

Patient support program